{"entity":{"id":"nct06514794","kind":"trial","name":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","aka":[],"tldr":"A phase 2 trial of WU-CART-007 in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Allotera Therapeutics, now recruiting.","summary":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) is a phase 2 interventional study registered as NCT06514794 by Allotera Therapeutics, with 125 participants planned, started 2025-01-31 and due to reach its primary completion in 2026-12-30. Interventions recorded: WU-CART-007.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06514794","url":"https://clinicaltrials.gov/study/NCT06514794"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["allotera-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06514794","phase":"2","setting":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)","sponsor":"Allotera Therapeutics","enrolled":125,"outcomes":[]},"route":"/trials/nct06514794/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","route":"/companies/allotera-therapeutics/"}]}}